HLB Pharmaceutical Receives Ministerial Award at 'Korea Strong Small and Medium Business Awards'

HLB Pharmaceutical announced on the 17th that it received the Minister of SMEs and Startups Award at the ‘7th 2024 Korea Strong Small and Medium Enterprise Awards’ hosted by the Korea Strong Small and Medium Enterprise Association. This recognition was for developing microfluidic equipment capable of automatically producing long-acting injectable microparticles for the first time in Korea.

HLB Pharmaceutical developed the equipment in accordance with the Ministry of Food and Drug Safety’s guidelines on ‘Continuous Manufacturing Processes for Active Pharmaceutical Ingredients and Finished Dosage Forms (ICH Q13).’ It can be utilized in the production of various long-acting injectables currently under development, including obesity and diabetes treatments, anticoagulants, and dementia therapies.

The most significant achievement is the introduction of an automated production process, moving away from the conventional manual production system. The equipment can continuously manufacture microparticles, the core technology of long-acting injectables, in uniform sizes and allows real-time monitoring of the manufacturing process.

HLB Pharmaceutical won the grand prize in the innovative pharmaceuticals category last year. This was in recognition of obtaining IND approval for Phase 1 clinical trials developing ‘Apixaban,’ a thrombosis treatment, as a long-acting injectable. Following this, the company was honored again this year by being named a ‘Strong Small and Medium Enterprise’ for two consecutive years.

Jung Doo-yong, Senior Researcher at HLB Pharmaceutical, said, "With the establishment of the microfluidic automated production facility, the research and development of long-acting injectables will accelerate." He added, "Not only for long-acting injectables but also for the production of various pharmaceuticals, this technology is expected to greatly contribute to our company in the future."

Park Jae-hyung, CEO of HLB Pharmaceutical, emphasized, "Microparticle production technology is increasingly gaining attention in the global market." He stressed, "We will not spare investment in research on long-acting injectables to ensure that research outcomes translate into commercial sales."

원본보기 아이콘

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.